FASN Antibody - #DF6106

(11)   (8)  
Product: FASN Antibody
Catalog: DF6106
Description: Rabbit polyclonal antibody to FASN
Application: WB IHC
Cited expt.: WB, IHC
Reactivity: Human, Mouse, Rat
Prediction: Zebrafish, Bovine, Horse, Dog
Mol.Wt.: 272kDa; 273kD(Calculated).
Uniprot: P49327
RRID: AB_2811172

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Zebrafish(89%), Bovine(100%), Horse(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
FASN Antibody detects endogenous levels of total FASN.
RRID:
AB_2811172
Cite Format: Affinity Biosciences Cat# DF6106, RRID:AB_2811172.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

[Acyl-carrier-protein] S acetyltransferase; [Acyl-carrier-protein] S malonyltransferase; 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-oxoacyl-[acyl-carrier-protein] synthase; Enoyl-[acyl-carrier-protein] reductase; FAS; FAS_HUMAN; FASN; Fatty acid synthase; MGC14367; MGC15706; OA 519; Oleoyl-[acyl-carrier-protein] hydrolase; SDR27X1; Short chain dehydrogenase/reductase family 27X member 1;

Immunogens

Immunogen:

A synthesized peptide derived from human FASN, corresponding to a region within N-terminal amino acids.

Uniprot:

P49327(FAS_HUMAN) >>Visit HPA database.

Gene(ID):
FASN(2194)
Expression:
P49327 FAS_HUMAN:

Ubiquitous. Prominent expression in brain, lung, and liver.

Description:
Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1).Recently, increased expression of FASN has emerged as a phenotype common to most human carcinomas. In breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).
Sequence:
MEEVVIAGMSGKLPESENLQEFWDNLIGGVDMVTDDDRRWKAGLYGLPRRSGKLKDLSRFDASFFGVHPKQAHTMDPQLRLLLEVTYEAIVDGGINPDSLRGTHTGVWVGVSGSETSEALSRDPETLVGYSMVGCQRAMMANRLSFFFDFRGPSIALDTACSSSLMALQNAYQAIHSGQCPAAIVGGINVLLKPNTSVQFLRLGMLSPEGTCKAFDTAGNGYCRSEGVVAVLLTKKSLARRVYATILNAGTNTDGFKEQGVTFPSGDIQEQLIRSLYQSAGVAPESFEYIEAHGTGTKVGDPQELNGITRALCATRQEPLLIGSTKSNMGHPEPASGLAALAKVLLSLEHGLWAPNLHFHSPNPEIPALLDGRLQVVDQPLPVRGGNVGINSFGFGGSNVHIILRPNTQPPPAPAPHATLPRLLRASGRTPEAVQKLLEQGLRHSQDLAFLSMLNDIAAVPATAMPFRGYAVLGGERGGPEVQQVPAGERPLWFICSGMGTQWRGMGLSLMRLDRFRDSILRSDEAVKPFGLKVSQLLLSTDESTFDDIVHSFVSLTAIQIGLIDLLSCMGLRPDGIVGHSLGEVACGYADGCLSQEEAVLAAYWRGQCIKEAHLPPGAMAAVGLSWEECKQRCPPGVVPACHNSKDTVTISGPQAPVFEFVEQLRKEGVFAKEVRTGGMAFHSYFMEAIAPPLLQELKKVIREPKPRSARWLSTSIPEAQWHSSLARTSSAEYNVNNLVSPVLFQEALWHVPEHAVVLEIAPHALLQAVLKRGLKPSCTIIPLMKKDHRDNLEFFLAGIGRLHLSGIDANPNALFPPVEFPAPRGTPLISPLIKWDHSLAWDVPAAEDFPNGSGSPSAAIYNIDTSSESPDHYLVDHTLDGRVLFPATGYLSIVWKTLARALGLGVEQLPVVFEDVVLHQATILPKTGTVSLEVRLLEASRAFEVSENGNLVVSGKVYQWDDPDPRLFDHPESPTPNPTEPLFLAQAEVYKELRLRGYDYGPHFQGILEASLEGDSGRLLWKDNWVSFMDTMLQMSILGSAKHGLYLPTRVTAIHIDPATHRQKLYTLQDKAQVADVVVSRWLRVTVAGGVHISGLHTESAPRRQQEQQVPILEKFCFTPHTEEGCLSERAALQEELQLCKGLVQALQTKVTQQGLKMVVPGLDGAQIPRDPSQQELPRLLSAACRLQLNGNLQLELAQVLAQERPKLPEDPLLSGLLDSPALKACLDTAVENMPSLKMKVVEVLAGHGHLYSRIPGLLSPHPLLQLSYTATDRHPQALEAAQAELQQHDVAQGQWDPADPAPSALGSADLLVCNCAVAALGDPASALSNMVAALREGGFLLLHTLLRGHPLGDIVAFLTSTEPQYGQGILSQDAWESLFSRVSLRLVGLKKSFYGSTLFLCRRPTPQDSPIFLPVDDTSFRWVESLKGILADEDSSRPVWLKAINCATSGVVGLVNCLRREPGGNRLRCVLLSNLSSTSHVPEVDPGSAELQKVLQGDLVMNVYRDGAWGAFRHFLLEEDKPEEPTAHAFVSTLTRGDLSSIRWVCSSLRHAQPTCPGAQLCTVYYASLNFRDIMLATGKLSPDAIPGKWTSQDSLLGMEFSGRDASGKRVMGLVPAKGLATSVLLSPDFLWDVPSNWTLEEAASVPVVYSTAYYALVVRGRVRPGETLLIHSGSGGVGQAAIAIALSLGCRVFTTVGSAEKRAYLQARFPQLDSTSFANSRDTSFEQHVLWHTGGKGVDLVLNSLAEEKLQASVRCLATHGRFLEIGKFDLSQNHPLGMAIFLKNVTFHGVLLDAFFNESSADWREVWALVQAGIRDGVVRPLKCTVFHGAQVEDAFRYMAQGKHIGKVVVQVLAEEPEAVLKGAKPKLMSAISKTFCPAHKSYIIAGGLGGFGLELAQWLIQRGVQKLVLTSRSGIRTGYQAKQVRRWRRQGVQVQVSTSNISSLEGARGLIAEAAQLGPVGGVFNLAVVLRDGLLENQTPEFFQDVCKPKYSGTLNLDRVTREACPELDYFVVFSSVSCGRGNAGQSNYGFANSAMERICEKRRHEGLPGLAVQWGAIGDVGILVETMSTNDTIVSGTLPQRMASCLEVLDLFLNQPHMVLSSFVLAEKAAAYRDRDSQRDLVEAVAHILGIRDLAAVNLDSSLADLGLDSLMSVEVRQTLERELNLVLSVREVRQLTLRKLQELSSKADEASELACPTPKEDGLAQQQTQLNLRSLLVNPEGPTLMRLNSVQSSERPLFLVHPIEGSTTVFHSLASRLSIPTYGLQCTRAAPLDSIHSLAAYYIDCIRQVQPEGPYRVAGYSYGACVAFEMCSQLQAQQSPAPTHNSLFLFDGSPTYVLAYTQSYRAKLTPGCEAEAETEAICFFVQQFTDMEHNRVLEALLPLKGLEERVAAAVDLIIKSHQGLDRQELSFAARSFYYKLRAAEQYTPKAKYHGNVMLLRAKTGGAYGEDLGADYNLSQVCDGKVSVHVIEGDHRTLLEGSGLESIISIIHSSLAEPRVSVREG

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Bovine
100
Dog
100
Zebrafish
89
Chicken
78
Pig
0
Sheep
0
Xenopus
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Fatty acid synthetase catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH. This multifunctional protein has 7 catalytic activities as an acyl carrier protein.

Subcellular Location:

Cytoplasm. Melanosome.
Note: Identified by mass spectrometry in melanosome fractions from stage I to stage IV.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Ubiquitous. Prominent expression in brain, lung, and liver.

Research Fields

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Metabolism > Lipid metabolism > Fatty acid biosynthesis.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Fatty acid metabolism.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

References

1). β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2021 (PubMed: 33341045) [IF=6.9]

Application: WB    Species: Rat    Sample: hepatic tissue

Fig. 4. β-PAE inhibits the expression of hepatic lipid synthesis-related proteins and genes in HFD-fed rats. (A–F) Western blot analysis on the expression of proteins referred to hepatic lipid synthesis including SREBP-1c, ACC1, p-ACC1, FASN, SCD1 and HMG-CR; (G–H) The mRNA expression of SREBP-1c and HMG-CR. Data are presented as the mean ± SD (n = 6~8). ##p < 0.01 vs. NC group; *p < 0.05, **p < 0.01 vs. Model group.
2). Sirtuin 3‐mediated deacetylation of acyl‐CoA synthetase family member 3 by protocatechuic acid attenuates nonalcoholic fatty liver disease. British Journal of Pharmacology, 2020 (PubMed: 32520409) [IF=6.8]

Application: WB    Species: Mouse    Sample: livers

Figure 3. PCA promotes fatty acid metabolism through SIRT3 activation. (A-E) Western blotting and real-time PCR analysis of hepatic FASN, SREBP-1c, CPT1, Acox1 and PPARα protein (n=5) and mRNA (n=6) levels in mouse livers. *P< 0.05 vs. the WT ND group, #P< 0.05 vs. the WT HFD group, &P< 0.05 vs. the SIRT3−/− ND group. (F-I) The protein expression of FASN, SREBP-1c, CPT1, Acox1, PPARα and SIRT3 was measured by Western blotting (n=5). The mRNA levels of (J) FASN, SREBP-1c (K) CPT1, Acox1 and PPARα were measured with real-time PCR (n=6). *P< 0.05 vs. the si-Control group, #P< 0.05 vs. the si-Control+PA group, &P< 0.05 vs. the si-Control+PA+PCA group.
3). FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism. Frontiers in Pharmacology, 2022 (PubMed: 35517790) [IF=5.6]

Application: WB    Species: mouse    Sample: liver

FIGURE 2 | Knockdown of FGF9 in the liver of DIO mice exacerbated fatty liver phenotype.. (H) Representative Western blotting analysis of genes involved in lipid synthesis in mice as described in (A).
4). Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF-κB Signaling Pathway. International Journal of Molecular Sciences, 2021 (PubMed: 34576229) [IF=5.6]

Application: WB    Species: Human    Sample: SK-HEP-1 cells

Figure 3 Effect of methyl brevifolincarboxylate (MBC) on expression of lipogenesis and lipid oxidation mRNA and proteins in OA-treated SK-HEP-1 cells (A), and primary murine hepatocytes (B). Cells were treated with 0.5 mM of OA, and different concentrations of MBC (0, 20, 40, 60, and 80μM) for 48 h. Total RNA was isolated using a GENEzol reagent and mRNA was measured using qRT-PCR. Target gene mRNA levels were normalized to a reference gene β-actin. (C) Protein expression of FASN, ACC1, SREBP-1c, PPAR-α and (D) p-AMPK were detected by Western blot. All results are expressed as mean ± SD of three independent experiments. Data bars with similar letters were not significantly different (p ≤ 0.05).
5). Leptin Silencing Attenuates Lipid Accumulation through Sterol Regulatory Element-Binding Protein 1 Inhibition in Nasopharyngeal Carcinoma. International journal of molecular sciences, 2022 (PubMed: 35628510) [IF=5.6]

Application: IHC    Species: Mouse    Sample:

Figure 5. Leptin inhibition attenuates SREBP1 expression in vivo. (A) Mouse body weights were measured in shcontrol and shleptin groups. (B) IHC was performed to investigate the protein expression levels of SREBP1, FASN, and SCD1 in shcontrol and shleptin xenograft tumors. The quantifications of IHC staining are shown. The data are presented as the mean ± SD. ***: p < 0.001; n.s.: not significant.
6). Sex hormone-binding globulin improves lipid metabolism and reduces inflammation in subcutaneous adipose tissue of metabolic syndrome-affected horses. Frontiers in molecular biosciences, 2023 (PubMed: 38146533) [IF=5.0]

Application: WB    Species: Human    Sample: adipose tissue

FIGURE 8 Influence of SHBG treatment of lipid metabolism related modulators interplay in SAT (A–N). The relative expression levels of LPL (A), SCD (B), PNPLA2 (C), PLIN1 (D), PPARA (E), FASN (F) in SAT were analyzed by RT-PCR. Protein levels of LPL (G), PLIN1 (H), FASN (I), SCD1 (J), ATGL (K, L) and HSL (M) were analyzed by Western blot ((N), representative membranes). Representative data are shown as mean ± SD.
7). Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice. International Immunopharmacology, 2023 (PubMed: 36822098) [IF=4.8]
8). microRNA-378b regulates ethanol-induced hepatic steatosis by targeting CaMKK2 to mediate lipid metabolism. Bioengineered, 2021 (PubMed: 34898362) [IF=4.2]

Application: WB    Species: Human    Sample: L-02 cells

Figure 3.miR-378b over-expression disturbs lipid metabolism in L-02 cells. (a) The TC level in L-02 cells. (b) The TG level in L-02 cells. (c) The expression level of miR-378b in L-02 cells. (d) mRNA expression levels of CaMKK2 in L-02 cells. (e) Western blot analysis for protein expression of CaMKK2 and p-AMPK/AMPK. (f) mRNA expression levels and protein expression levels for PPARα and CPT1. (g) mRNA expression levels and protein expression levels for FASN and SREBP1c. (h) Western blot analysis for protein expression of p-ACC/ACC. All data are expressed as the mean ± SD of at least three separate experiments. *p < 0.05, **p < 0.01 vs. control. #p < 0.05, ##p < 0.01 vs. miR-378b-mimics NC
9). Augmentation of 3β-hydroxysteroid-Δ24 Reductase (DHCR24) Expression Induced by Bovine Viral Diarrhea Virus Infection Facilitates Viral Replication via Promoting Cholesterol Synthesis. Journal of Virology, 2022 (PubMed: 36468862) [IF=4.0]

Application: WB    Species: bovine    Sample: bovine cells

FIG 1 (A) Cholesterol synthesis pathway. (B) Heat map of the key genes (transcriptomic data) and corresponding proteins (proteomic data) involved in lipid metabolism in bovine viral diarrhea virus (BVDV)-infected bovine cells. (C, D) Identification of differentially expressed genes by quantitative reverse transcription-PCR (qRT-PCR) (C) and corresponding proteins by Western blotting (D). HMGCS1, 3- hydroxy-3-methylglutaryl-coenzyme A synthase 1; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; MVK, mevalonate kinase; PMVK, phosphomevalonate kinase; MVD, diphosphomevalonate decarboxylase; FDPS, farnesyl diphosphate synthase; FDFT1, farnesyl diphosphate farnesyltransferase 1; SQLE, squalene epoxidase; GGPS, geranylgeranyl pyrophosphate synthase; LSS, lanosterol synthase; D8D7I, 3β-hydroxysterol-Δ8,7-isomerase; C5SD, 3β-hydroxysterol-C5 desaturase; DHCR7, 7-dehydrocholesterol reductase; DHCR24, 3β-hydroxysteroid-Δ24 reductase; SCD1, stearoyl-CoA desaturase; FASN, fatty acid synthase; ACACA, acetyl coenzyme A carboxylase alpha.
10). Peptides released from bovine α-lactalbumin by simulated digestion alleviated free fatty acids-induced lipid accumulation in HepG2 cells. Journal of Functional Foods, 2021 [IF=3.8]
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.